CA2713458A1 - Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner - Google Patents

Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner Download PDF

Info

Publication number
CA2713458A1
CA2713458A1 CA2713458A CA2713458A CA2713458A1 CA 2713458 A1 CA2713458 A1 CA 2713458A1 CA 2713458 A CA2713458 A CA 2713458A CA 2713458 A CA2713458 A CA 2713458A CA 2713458 A1 CA2713458 A1 CA 2713458A1
Authority
CA
Canada
Prior art keywords
mrna
polynucleotide
target
composition
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2713458A
Other languages
English (en)
French (fr)
Inventor
Xabier Abad Lloret
Maria Purificacion Fortes Alonso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2713458A1 publication Critical patent/CA2713458A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/50Physical structure
    • C12N2310/53Physical structure partially self-complementary or closed
    • C12N2310/531Stem-loop; Hairpin
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • AIDS & HIV (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA2713458A 2008-01-29 2009-01-29 Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner Abandoned CA2713458A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200800222 2008-01-29
ES200800222 2008-01-29
PCT/ES2009/000045 WO2009095517A2 (es) 2008-01-29 2009-01-29 Métodos y composiciones capaces de provocar un silenciamiento post-transcripcional de la expresión génica de forma sinérgica

Publications (1)

Publication Number Publication Date
CA2713458A1 true CA2713458A1 (en) 2009-08-06

Family

ID=40807539

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2713458A Abandoned CA2713458A1 (en) 2008-01-29 2009-01-29 Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner

Country Status (10)

Country Link
US (1) US20110030075A1 (enExample)
EP (1) EP2246432A2 (enExample)
JP (1) JP2011510647A (enExample)
CN (1) CN101981189A (enExample)
AU (1) AU2009209571A1 (enExample)
BR (1) BRPI0906657A2 (enExample)
CA (1) CA2713458A1 (enExample)
MX (1) MX2010008326A (enExample)
RU (1) RU2010136040A (enExample)
WO (1) WO2009095517A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9441221B2 (en) 2007-03-30 2016-09-13 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US8343941B2 (en) 2007-03-30 2013-01-01 Rutgers, The State University Of New Jersey Compositions and methods for gene silencing
US8907075B2 (en) 2007-03-30 2014-12-09 Samuel Ian Gunderson Compositions and methods for gene silencing
WO2012045894A1 (es) * 2010-10-05 2012-04-12 Proyecto De Biomedicina Cima, S.L. Compuestos y composiciones para el tratamiento de enfermedades debidas a la infección por el virus de la hepatitis b
WO2014172669A1 (en) * 2013-04-20 2014-10-23 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus delivery of exon 2-targeted u7snrna polynucleotide constructs
EP2853595A1 (en) * 2013-09-30 2015-04-01 Soluventis GmbH NOTCH 1 specific siRNA molecules
CN107746857B (zh) * 2017-08-07 2021-02-05 中国农业大学 一种抑制基因表达的rna干扰方法
CN108893487A (zh) * 2018-07-19 2018-11-27 中国农业科学院北京畜牧兽医研究所 一种含有C-Myc蛋白融合标签的植物表达质粒载体及其载体的构建方法
CA3132388A1 (en) * 2019-03-08 2020-09-17 Rutgers, The State University Of New Jersey Compositions and methods for treating huntington's disease
CN114159459A (zh) * 2021-12-20 2022-03-11 塔里木大学 miR-26a在制备治疗子宫内膜炎的药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910488A (en) 1993-06-07 1999-06-08 Vical Incorporated Plasmids suitable for gene therapy
EP0833907A1 (en) 1995-06-23 1998-04-08 President And Fellows Of Harvard College Transcriptional regulation of genes encoding vascular endothelial growth factor receptors
US6692910B2 (en) * 1997-07-28 2004-02-17 The University Of Connecticut Inhibition of a target messenger RNA with a modified U1 small nuclear RNA
WO2002083908A1 (es) * 2001-03-30 2002-10-24 Fundacion Para La Investigacion Medica Aplicada Procedimiento de inhibicion reversible de la expresion genica mediante ribonucleoproteinas modificadas
WO2003029459A2 (en) 2001-09-28 2003-04-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Micro-rna molecules
PT1504126E (pt) 2002-05-03 2014-06-02 Univ Duke Um método para regular a expressão génica
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
US20080131940A1 (en) 2004-06-25 2008-06-05 Robert Chiu Target Cell-Specific Short Interfering Rna and Methods of Use Thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
EP1945779B1 (en) 2005-10-20 2013-03-06 UniQure IP B.V. Improved aav vectors produced in insect cells
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
CN101506369B (zh) 2006-06-21 2014-02-12 尤尼克尔生物制药股份有限公司 具有经修饰的用于在昆虫细胞中产生aav的aav-rep78翻译起始密码子的载体
GB0701722D0 (en) * 2007-01-30 2007-03-07 Scottish Crop Res Inst Inhibition of gene expression

Also Published As

Publication number Publication date
RU2010136040A (ru) 2012-03-10
EP2246432A2 (en) 2010-11-03
US20110030075A1 (en) 2011-02-03
MX2010008326A (es) 2010-08-18
JP2011510647A (ja) 2011-04-07
CN101981189A (zh) 2011-02-23
BRPI0906657A2 (pt) 2015-07-14
AU2009209571A1 (en) 2009-08-06
WO2009095517A3 (es) 2009-09-24
WO2009095517A2 (es) 2009-08-06

Similar Documents

Publication Publication Date Title
EP2246432A2 (en) Methods and compositions capable of causing post-transcriptional silencing of gene expression in a synergic manner
US8980855B2 (en) Minor groove binder (MGB)-oligonucleotide miRNA antagonists
DK2853597T3 (en) RNA INTERFERENCE-INducing NUCLEIC ACID MOLECULES WITH CELL PENETENING EQUIPMENT AND USE THEREOF
AU2014284836B2 (en) Respiratory disease-related gene specific siRNA, double-helical oligo RNA structure containing siRNA, compositon containing same for preventing or treating respiratory disease
US20090118206A1 (en) Rna interference for the treatment of gain-of-function disorders
CA2980339A1 (en) Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
US20110054012A1 (en) Methods and Compositions for Increasing Gene Expression
Imbert et al. Lowering mutant huntingtin using tricyclo-DNA antisense oligonucleotides as a therapeutic approach for Huntington's disease
US20200199625A1 (en) RNAi induced reduction of ataxin-3 for the treatment of Spinocerebellar ataxia type 3
JP2022548399A (ja) 肝細胞核因子4-アルファ(HNF4α)遺伝子発現をモジュレートするための組成物および方法
WO2016030501A1 (en) Synthetic alu-retrotransposon vectors for gene therapy
Strings-Ufombah et al. BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
US20140255353A1 (en) Compositions, kits and methods for treating obesity, diabetes and hyperglycemia
US20230287427A1 (en) Inhibition of lncExACT1 to Treat Heart Disease
JP2022541212A (ja) 治療的使用のための、ヒト遺伝子JAK1又はJAK3の発現を標的とするSiRNA配列
WO2012177565A2 (en) Regulation of macrophage activation using mir - 125b
WO2023220719A2 (en) Method for treatment of myotonic dystrophy combining protein expression and rna interference vector delivery with tissue detargeting
WO2025202080A1 (en) Acta1 expression control elements
CN116814618A (zh) 特异性抑制ATG16L1表达的siRNA或shRNA
WO2024254244A2 (en) RNAi TARGETING HNRNPH2 MISSENSE MUTATIONS FOR TREATMENT OF BAIN SYNDROME
WO2024048528A1 (ja) 心疾患及びラミノパチーの予防及び/又は治療剤

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20150129